All In Biotech

Drug Trial Radar · NCT06973291

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

A Phase 3, Randomized, Multicenter, Double-Blind Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib (TAK-279) Compared to Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Jul 9, 2025

Primary completion

Apr 22, 2026

Study completion Apr 22, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

Conditions

  • Plaque Psoriasis

Interventions

  • ZasocitinibDrug

    Zasocitinib tablets.

  • DeucravacitinibDrug

    Deucravacitinib capsules.

  • Placebo to match zasocitinibDrug

    Zasocitinib matching placebo tablets.

  • Placebo to match deucravacitinibDrug

    Deucravacitinib matching placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16Time frame: At Week 16

Locations

113 sites in 8 countries. Site status is shown where the registry gives one.

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Zenith Research, Inc.

    Beverly Hills, California

  • First OC Dermatology Research Inc.

    Fountain Valley, California

  • UNISON Clinical Trials (Shahram Jacobs md inc.)

    Sherman Oaks, California

  • Central Connecticut Dermatology, PLLC

    Cromwell, Connecticut

  • Yale University School of Medicine

    New Haven, Connecticut

  • Direct Helpers Research Center

    Hialeah, Florida

  • San Marcus Research Clinic Inc

    Miami Lakes, Florida

  • Advanced Clinical Research Institute

    Tampa, Florida

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • Endeavor Health Clinical Trials

    Skokie, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Lawrence J Green, MD LLC

    Rockville, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • JDR Dermatology Research, LLC

    Las Vegas, Nevada

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • Markowitz Medical PLLC dba OptiSkin Medical

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Bexley Dermatology Research - Probity - PPDS

    Bexley, Ohio

  • Apex Clinical Research Center, LLC - Canton

    Canton, Ohio

  • Apex Clinical Research Center, LLC - Mayfield Heights

    Mayfield Heights, Ohio

  • UPMC Department of Dermatology

    Pittsburgh, Pennsylvania

  • Goodlettsville Dermatology Research

    Goodlettsville, Tennessee

  • Arlington Research Center

    Arlington, Texas

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • The University of Texas Health Science Center at Houston (UTHSC-H)

    Bellaire, Texas

  • Reveal Research Institute

    Dallas, Texas

  • San Antonio

    San Antonio, Texas

  • Texas Dermatology and Laser Specialists-San Antonio

    San Antonio, Texas

  • Houston Center for Clinical Research, LLC

    Sugar Land, Texas

  • Multiprofile Hospital For Active Treatment Dr Tota Venkova

    Gabrovo, Bulgaria

  • Diagnostic Consultative Center Sveti Georgi EOOD

    Haskovo, Bulgaria

  • Medical Center Medconsult Pleven - Lovech Branch

    Lovech, Bulgaria

  • Medical Centre Femiclinic EOOD

    Sofia, Dianabad District, Bulgaria

  • Medical Center Unimed EOOD-Sevlievo

    Sevlievo, Gabrovo, Bulgaria

  • Medical Center Asklepii OOD

    Dupnitsa, Kyustendil, Bulgaria

  • Diagnostic and Consulting Center Aleksandrovska EOOD

    Sofia, Sofia-Grad, Bulgaria

  • Medical Center Hera EOOD-Sofia

    Sofia, Sofia-Grad, Bulgaria

  • Diagnostic Consultative Center XXVIII - Sofia - EOOD

    Sofia, Sofia-Grad, Bulgaria

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.